Co-Authors
This is a "connection" page, showing publications co-authored by GORDON B MILLS and ALEXANDER LAZAR.
Connection Strength
0.664
-
A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer. 2008 Oct 21; 99(8):1265-8.
Score: 0.085
-
Multiplatform Analysis of Intratumoral PTEN Heterogeneity in Melanoma. J Invest Dermatol. 2023 09; 143(9):1779-1787.e1.
Score: 0.058
-
Immuno-genomic landscape of osteosarcoma. Nat Commun. 2020 02 21; 11(1):1008.
Score: 0.047
-
Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018 08 09; 174(4):1034-1035.
Score: 0.042
-
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell. 2018 04 05; 173(2):305-320.e10.
Score: 0.041
-
Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018 04 05; 173(2):371-385.e18.
Score: 0.041
-
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. 2018 04 09; 33(4):690-705.e9.
Score: 0.041
-
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2018 01 08; 33(1):151.
Score: 0.040
-
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2017 08 14; 32(2):204-220.e15.
Score: 0.039
-
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168.
Score: 0.037
-
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol. 2015 Nov; 144(5):713-21.
Score: 0.035
-
Nuclear PTEN tumor-suppressor functions through maintaining heterochromatin structure. Cell Cycle. 2015; 14(14):2323-32.
Score: 0.033
-
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
Score: 0.032
-
Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene. 2011 Jan 27; 30(4):457-70.
Score: 0.024
-
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res. 2009 Dec 15; 15(24):7538-7546.
Score: 0.023
-
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther. 2009 Aug; 8(8):2079-85.
Score: 0.023
-
Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther. 2009 May; 8(5):1157-68.
Score: 0.022